OBJECT: This pilot study evaluated the utility of 3'-deoxy-3'[18F]-fluorothymidine ([(18)F]-FLT) positron emission tomography (PET) to predict response to neoadjuvant therapy that included cetuximab in patients with wild-type KRAS rectal cancers. METHODS: Baseline [(18)F]-FLT PET was collected prior to treatment initiation. Follow-up [(18)F]-FLT was collected after three weekly infusions of cetuximab, and following a combined regimen of cetuximab, 5-FU, and radiation. Imaging-matched biopsies were collected with each PET study. RESULTS: Diminished [(18)F]-FLT PET was observed in 3/4 of patients following cetuximab treatment alone and in all patients following combination therapy. Reduced [(18)F]-FLT PET following combination therapy predicted disease-free status at surgery. Overall, [(18)F]-FLT PET agreed with Ki67 immunoreactivity from biopsy samples and surgically resected tissue, and was predictive of treatment-induced rise in p27 levels. CONCLUSION: These results suggest that [(18)F]-FLT PET is a promising imaging biomarker to predict response to neoadjuvant therapy that included EGFR blockade with cetuximab in patients with rectal cancer.
OBJECT: This pilot study evaluated the utility of 3'-deoxy-3'[18F]-fluorothymidine ([(18)F]-FLT) positron emission tomography (PET) to predict response to neoadjuvant therapy that included cetuximab in patients with wild-type KRASrectal cancers. METHODS: Baseline [(18)F]-FLT PET was collected prior to treatment initiation. Follow-up [(18)F]-FLT was collected after three weekly infusions of cetuximab, and following a combined regimen of cetuximab, 5-FU, and radiation. Imaging-matched biopsies were collected with each PET study. RESULTS: Diminished [(18)F]-FLT PET was observed in 3/4 of patients following cetuximab treatment alone and in all patients following combination therapy. Reduced [(18)F]-FLT PET following combination therapy predicted disease-free status at surgery. Overall, [(18)F]-FLT PET agreed with Ki67 immunoreactivity from biopsy samples and surgically resected tissue, and was predictive of treatment-induced rise in p27 levels. CONCLUSION: These results suggest that [(18)F]-FLT PET is a promising imaging biomarker to predict response to neoadjuvant therapy that included EGFR blockade with cetuximab in patients with rectal cancer.
Authors: Farrokh Dehdashti; Perry W Grigsby; Robert J Myerson; Ilke Nalbantoglu; Changqing Ma; Barry A Siegel Journal: Mol Imaging Biol Date: 2013-02 Impact factor: 3.488
Authors: Eliot T McKinley; R Adam Smith; Jarred P Tanksley; Mary Kay Washington; Ronald Walker; Robert J Coffey; H Charles Manning Journal: Ann Nucl Med Date: 2012-07-22 Impact factor: 2.668
Authors: Cathy C Zhang; Zhengming Yan; Wenlin Li; Kyle Kuszpit; Cory L Painter; Qin Zhang; Patrick B Lappin; Tim Nichols; Maruja E Lira; Timothy Affolter; Neeta R Fahey; Carleen Cullinane; Mary Spilker; Kenneth Zasadny; Peter O'Brien; Dana Buckman; Anthony Wong; James G Christensen Journal: Clin Cancer Res Date: 2011-12-14 Impact factor: 12.531
Authors: Seung Jun Oh; Christoph Mosdzianowski; Dae Yoon Chi; Jung Young Kim; Se Hun Kang; Jin Sook Ryu; Jeong Seok Yeo; Dae Hyuk Moon Journal: Nucl Med Biol Date: 2004-08 Impact factor: 2.408
Authors: A F Shields; J R Grierson; B M Dohmen; H J Machulla; J C Stayanoff; J M Lawhorn-Crews; J E Obradovich; O Muzik; T J Mangner Journal: Nat Med Date: 1998-11 Impact factor: 53.440
Authors: Leonard B Saltz; Neal J Meropol; Patrick J Loehrer; Michael N Needle; Justin Kopit; Robert J Mayer Journal: J Clin Oncol Date: 2004-03-01 Impact factor: 44.544
Authors: Eliot T McKinley; Gregory D Ayers; R Adam Smith; Samir A Saleh; Ping Zhao; Mary Kay Washington; Robert J Coffey; H Charles Manning Journal: PLoS One Date: 2013-03-15 Impact factor: 3.240
Authors: Benjamin E Ueberroth; Jawana M Lawhorn-Crews; Lance K Heilbrun; Daryn W Smith; Janice Akoury; Rouba Ali-Fehmi; Nicole T Eiseler; Anthony F Shields Journal: Ann Nucl Med Date: 2019-02-27 Impact factor: 2.668
Authors: Matthew Scarpelli; Christopher Zahm; Scott Perlman; Douglas G McNeel; Robert Jeraj; Glenn Liu Journal: J Immunother Cancer Date: 2019-01-30 Impact factor: 13.751